Organon (NYSE:OGN) announced Tuesday the acquisition of regulatory and commercial rights linked to Tofidence, a biosimilar ...

Biosimilar challenges include complex manufacturing processes and regulatory obstacles, offset by less regulated market ...

Cambridge-based biotechnology company Biogen Inc. announced Monday that it will move its global headquarters to a new ...

Bio-Thera Solutions, the developer of the biosimilar, will continue to hold manufacturing rights in the US market.

We are encouraged by the FDA’s Fast Track designation for BIIB080, which highlights the urgent need for innovative treatments targeting tau pathology in Alzheimer’s disease,” said Priya Singhal, M.D., ...

Tofidence is indicated in certain patients for the treatment of moderate to severe rheumatoid arthritis, giant cell arteritis ...

Organon (OGN) announced that it has acquired from Biogen (BIIB) regulatory and commercial rights in the U.S. for Tofidence, a biosimilar to ...

As part of a bid to consolidate its footprint in Massachusetts, Biogen is foregoing its old home base to put down new roots ...

Fortunately, the S&P 500 recovered to new all-time highs by August 2020 and is now up about 150% from its COVID lows.

Biogen enhances its portfolio and margins amidst market challenges and competition. Click here to find out why BIIB stock is ...

Originally approved by the FDA in September 2023, Biogen's Tofidence became the first tocilizumab biosimilar available in the ...

Biogen Inc. plans to move its headquarters into a 16-story Kendall Square tower to be developed by MIT and BioMed Realty ...